Wanbury enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


609	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.6	1.6	4.2	3.4	1.5
215	215	173	110	64.1
822	—	—	—	—
214	214	169	107	62.7
₹235.36	—	—	—	—

360	360	233	138	56.9
59.9%	59.9%	74.5%	79.7%	112.8%
0.26×	—	—	—	—

1.26×	—	—	—	—
8.34×	—	—	—	—
9.81×	—	—	—	—
653	650	600	576	500
98.6	107	76.3	70.0	23.2
83.8	92.4	63.0	57.0	10.8
—	31.5	26.1	4.0	19.8
−27.5	−27.5	−22.9	4.0	19.8
—	−27.5	−22.9	3.6	19.8
—	59.1	49.0	0.0	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WANBURY₹174.16

Wanbury Limited

· Pharma & Health

₹ CrorePeersAHCL ANUHPHR BAJAJHCARE THEMISMED ZIMLAB LINCOLN SIGACHI VALIANTLABMcap ₹609 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	608.5
- Cash, Equiv & ST Investments	1.5	3.4	4.2	1.6	1.6
+ Total Debt	64.1	110.0	173.2	215.5	215.5
Enterprise Value	—	—	—	—	822.3
Net Debt (memo)	62.7	106.6	169.0	213.8	213.8
EV per Share	—	—	—	—	235.36

Total Capital	56.9	137.9	232.5	359.9	359.9
Total Debt/Total Capital	112.76	79.74	74.51	59.86	59.86
Total Debt/EV	—	—	—	—	0.26

EV/Sales	—	—	—	—	1.26
EV/EBITDA	—	—	—	—	8.34
EV/EBIT	—	—	—	—	9.81
Reference Items — Trailing FY Values
Sales	499.6	575.6	599.5	650.3	652.7
EBITDA	23.2	70.0	76.3	106.8	98.6
EBIT	10.8	57.0	63.0	92.4	83.8
Operating Cash Flow	19.8	4.0	26.1	31.5	—
Free Cash Flow	19.8	4.0	-22.9	-27.5	-27.5
FCFF (free cash flow to the firm)	19.8	3.6	-22.9	-27.5	—
Capital Expenditure	0.0	0.0	49.0	59.1	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.